{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:01:29Z","timestamp":1773680489007,"version":"3.50.1"},"reference-count":49,"publisher":"Harborside Press, LLC","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:p>Peritoneal mesothelioma is an uncommon malignancy affecting approximately 300 new patients annually in the United States. Due to its low incidence, prospective clinical trials specific to this disease are scant. Recommendations regarding systemic therapy are mostly extrapolated from clinical trials conducted among patients with pleural mesothelioma. At present, the recommended first-line systemic treatment options may include immunotherapy with nivolumab plus ipilimumab or chemotherapy with pemetrexed plus either cisplatin or carboplatin. For second-line treatment, the other previously unchosen first-line option can be used. Off-label bevacizumab may be considered in combination with chemotherapy among carefully selected patients. The benefit of third-line treatment or beyond is less clear. Nonetheless, a number of single-agent regimens show modest activity. Anecdotal reports of children or young adults with peritoneal mesothelioma harboring <jats:italic>ALK<\/jats:italic> rearrangement have suggested the efficacy of ALK inhibitors for this rare population. In summary, there is a growing number of systemic therapy options for peritoneal mesothelioma. To gain a better insight into this disease, future prospective trials in mesothelioma should include more patients with peritoneal mesothelioma.<\/jats:p>","DOI":"10.6004\/jnccn.2024.7031","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T12:47:31Z","timestamp":1729082851000},"source":"Crossref","is-referenced-by-count":2,"title":["Systemic Therapy Options for Peritoneal Mesothelioma"],"prefix":"10.6004","volume":"22","author":[{"given":"Tawee","family":"Tanvetyanon","sequence":"first","affiliation":[{"name":"Thoracic Oncology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George R.","family":"Simon","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4047","reference":[{"key":"B1","author":"Centers for Disease Control and Prevention","unstructured":"Centers for Disease Control and Prevention. Incidence of malignant mesothelioma, 1999\u20132018: US cancer statistics data brief, no. 27. Accessed November 15, 2023. Available at: https:\/\/www.cdc.gov\/cancer\/uscs\/about\/data-briefs\/no27-incidence-malignant-mesothelioma-1999-2018.htm"},{"key":"B2","series-title":"J Clin Oncol","first-page":"2863","article-title":"Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma","volume":"36","author":"Panou V","year":"2018","unstructured":"Panou V, Gadiraju M, Wolin A,  Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma. J Clin Oncol 2018;36:2863\u20132871."},{"key":"B3","series-title":"Cancer Epidemiol","first-page":"106","article-title":"Incidence and survival of peritoneal malignant mesothelioma between 1989 and 2015: a population-based study","volume":"60","author":"Le Stang N","year":"2019","unstructured":"Le Stang N, Bouvier V, Glehen O,  Incidence and survival of peritoneal malignant mesothelioma between 1989 and 2015: a population-based study. Cancer Epidemiol 2019;60:106\u2013111."},{"key":"B4","series-title":"J Natl Compr Canc Netw","first-page":"981","article-title":"Principles of surgical management of peritoneal mesothelioma","volume":"21","author":"Steadman JA","year":"2023","unstructured":"Steadman JA, Grotz TE. Principles of surgical management of peritoneal mesothelioma. J Natl Compr Canc Netw 2023;21:981\u2013986."},{"key":"B5","series-title":"J Clin Oncol","first-page":"6237","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience","volume":"27","author":"Yan TD","year":"2009","unstructured":"Yan TD, Deraco M, Baratti D,  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 2009;27:6237\u20136242."},{"key":"B6","series-title":"J Thorac Oncol","first-page":"608","article-title":"The 2021 WHO Classification of Tumors of the Pleura: advances since the 2015 classification","volume":"17","author":"Sauter JL","year":"2022","unstructured":"Sauter JL, Dacic S, Galateau-Salle F,  The 2021 WHO Classification of Tumors of the Pleura: advances since the 2015 classification. J Thorac Oncol 2022;17:608\u2013622."},{"key":"B7","series-title":"J Natl Compr Canc Netw","first-page":"49","article-title":"Current concepts in the evaluation and treatment of patients with diffuse malignant peritoneal mesothelioma","volume":"10","author":"Turner K","year":"2012","unstructured":"Turner K, Varghese S, Alexander HR Jr Current concepts in the evaluation and treatment of patients with diffuse malignant peritoneal mesothelioma. J Natl Compr Canc Netw 2012;10:49\u201357."},{"key":"B8","article-title":"Mesothelioma: Peritoneal. Version 2.2023","author":"Ettinger DS","unstructured":"Ettinger DS, Wood DE, Stevenson J,  NCCN Clinical Practice Guidelines in Oncology: Mesothelioma: Peritoneal. Version 2.2023. Accessed November 15, 2023. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B9","series-title":"Lancet","first-page":"375","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas P","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK,  First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 2021;397:375\u2013386."},{"key":"B10","series-title":"Ann Oncol","first-page":"488","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters S","year":"2022","unstructured":"Peters S, Scherpereel A, Cornelissen R,  First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol 2022;33:488\u2013499."},{"key":"B11","series-title":"Lancet Oncol","first-page":"239","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel A","year":"2019","unstructured":"Scherpereel A, Mazieres J, Greillier L,  Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol 2019;20:239\u2013253."},{"key":"B12","series-title":"Clin Cancer Res","first-page":"446","article-title":"FDA approval summary: nivolumab in combination with ipilimumab for the treatment of unresectable malignant pleural mesothelioma","volume":"28","author":"Nakajima EC","year":"2022","unstructured":"Nakajima EC, Vellanki PJ, Larkins E,  FDA approval summary: nivolumab in combination with ipilimumab for the treatment of unresectable malignant pleural mesothelioma. Clin Cancer Res 2022;28:446\u2013451."},{"key":"B13","series-title":"J Clin Oncol","first-page":"161","article-title":"First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study","volume":"40","author":"Lenz HJ","year":"2022","unstructured":"Lenz HJ, Van Cutsem E, Luisa Limon M,  First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J Clin Oncol 2022;40:161\u2013170."},{"key":"B14","series-title":"Clin Colorectal Cancer","first-page":"371","article-title":"Response to ipilimumab and nivolumab in a patient with malignant peritoneal mesothelioma","volume":"21","author":"Rizzolo A","year":"2022","unstructured":"Rizzolo A, Ah-Lan KC, Nu TNT,  Response to ipilimumab and nivolumab in a patient with malignant peritoneal mesothelioma. Clin Colorectal Cancer 2022;21:371\u2013374."},{"key":"B15","series-title":"Lancet","first-page":"1405","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman G","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J,  Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 2016;387:1405\u20131414."},{"key":"B16","series-title":"JTO Clin Res Rep","first-page":"100280","article-title":"A real-world analysis of the use of systemic therapy in malignant pleural mesothelioma and the differential impacts on overall survival by practice pattern","volume":"3","author":"Kerrigan K","year":"2022","unstructured":"Kerrigan K, Jo Y, Chipman J,  A real-world analysis of the use of systemic therapy in malignant pleural mesothelioma and the differential impacts on overall survival by practice pattern. JTO Clin Res Rep 2022;3:100280."},{"key":"B17","series-title":"Lung Cancer","first-page":"567","article-title":"A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma","volume":"77","author":"Dowell JE","year":"2012","unstructured":"Dowell JE, Dunphy FR, Taub RN,  A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer 2012;77:567\u2013571."},{"key":"B18","series-title":"Br J Cancer","first-page":"552","article-title":"Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma","volume":"109","author":"Ceresoli GL","year":"2013","unstructured":"Ceresoli GL, Zucali PA, Mencoboni M,  Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. Br J Cancer 2013;109:552\u2013558."},{"key":"B19","author":"Prescribing information for bevacizumab injection, for intravenous use","unstructured":"Prescribing information for bevacizumab injection, for intravenous use. 2022. Accessed April 22, 2023. Available at: https:\/\/www.gene.com\/download\/pdf\/avastin_prescribing.pdf"},{"key":"B20","series-title":"J Clin Oncol","first-page":"2636","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang NJ","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J,  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636\u20132644."},{"key":"B21","series-title":"Mol Cancer Ther","first-page":"545","article-title":"Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy","volume":"1","author":"Niyikiza C","year":"2002","unstructured":"Niyikiza C, Baker SD, Seitz DE,  Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002;1:545\u2013552."},{"key":"B22","series-title":"J Clin Oncol","first-page":"1443","article-title":"Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma","volume":"24","author":"Ceresoli GL","year":"2006","unstructured":"Ceresoli GL, Zucali PA, Favaretto AG,  Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006;24:1443\u20131448."},{"key":"B23","series-title":"Lung Cancer","first-page":"211","article-title":"Malignant peritoneal mesothelioma\u2014results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent","volume":"64","author":"Carteni G","year":"2009","unstructured":"Carteni G, Manegold C, Garcia GM,  Malignant peritoneal mesothelioma\u2014results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer 2009;64:211\u2013218."},{"key":"B24","series-title":"Clin Lung Cancer","first-page":"40","article-title":"Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program","volume":"7","author":"J\u00e4nne PA","year":"2005","unstructured":"J\u00e4nne PA, Wozniak AJ, Belani CP,  Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer 2005;7:40\u201346."},{"key":"B25","series-title":"Clin Cancer Res","first-page":"2872","article-title":"Pemetrexed safety and pharmacokinetics in patients with third-space fluid","volume":"16","author":"Dickgreber NJ","year":"2010","unstructured":"Dickgreber NJ, Sorensen JB, Paz-Ares LG,  Pemetrexed safety and pharmacokinetics in patients with third-space fluid. Clin Cancer Res 2010;16:2872\u20132880."},{"key":"B26","series-title":"Clin Lung Cancer","first-page":"553","article-title":"Randomized study of maintenance pemetrexed versus observation for treatment of malignant pleural mesothelioma: CALGB 30901","volume":"21","author":"Dudek AZ","year":"2020","unstructured":"Dudek AZ, Wang X, Gu L,  Randomized study of maintenance pemetrexed versus observation for treatment of malignant pleural mesothelioma: CALGB 30901. Clin Lung Cancer 2020;21:553\u2013561.e1."},{"key":"B27","series-title":"Lung Cancer","first-page":"308","article-title":"Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia","volume":"64","author":"Lee CW","year":"2009","unstructured":"Lee CW, Murray N, Anderson H,  Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia. Lung Cancer 2009;64:308\u2013313."},{"key":"B28","series-title":"J Clin Oncol","first-page":"25","article-title":"Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study","volume":"17","author":"Byrne MJ","year":"1999","unstructured":"Byrne MJ, Davidson JA, Musk AW,  Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999;17:25\u201330."},{"key":"B29","series-title":"J Clin Oncol","first-page":"2509","article-title":"Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma","volume":"30","author":"Kindler HL","year":"2012","unstructured":"Kindler HL, Karrison TG, Gandara DR,  Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 2012;30:2509\u20132515."},{"key":"B30","series-title":"Cancer Discov","first-page":"2738","article-title":"Efficacy, safety, and biomarker analysis of combined PD-L1 (atezolizumab) and VEGF (bevacizumab) blockade in advanced malignant peritoneal mesothelioma","volume":"11","author":"Raghav K","year":"2021","unstructured":"Raghav K, Liu S, Overman MJ,  Efficacy, safety, and biomarker analysis of combined PD-L1 (atezolizumab) and VEGF (bevacizumab) blockade in advanced malignant peritoneal mesothelioma. Cancer Discov 2021;11:2738\u20132747."},{"key":"B31","series-title":"Lancet Oncol","first-page":"1530","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell DA","year":"2021","unstructured":"Fennell DA, Ewings S, Ottensmeier C,  Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol 2021;22:1530\u20131540."},{"key":"B32","series-title":"Lancet Oncol","first-page":"1438","article-title":"Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"22","author":"Pinto C","year":"2021","unstructured":"Pinto C, Zucali PA, Pagano M,  Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2021;22:1438\u20131447."},{"key":"B33","article-title":"NCCN Clinical Practice Guidelines in Oncology: Mesothelioma: Pleural","author":"Ettinger DS","unstructured":"Ettinger DS, Wood DE, Stevenson J,  NCCN Clinical Practice Guidelines in Oncology: Mesothelioma: Pleural. Version 1.2024. Accessed April 22, 2024. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B34","series-title":"Lancet Oncol","first-page":"540","article-title":"Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial","volume":"23","author":"Kindler HL","year":"2022","unstructured":"Kindler HL, Novello S, Bearz A,  Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. Lancet Oncol 2022;23:540\u2013552."},{"key":"B35","series-title":"EClinicalMedicine","first-page":"101432","article-title":"Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): a randomised, phase 2 trial","volume":"48","author":"Fennell DA","year":"2022","unstructured":"Fennell DA, Porter C, Lester J,  Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): a randomised, phase 2 trial. EClinicalMedicine 2022;48:101432."},{"key":"B36","series-title":"Lancet","first-page":"1685","article-title":"Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial","volume":"371","author":"Muers MF","year":"2008","unstructured":"Muers MF, Stephens RJ, Fisher P,  Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008;371:1685\u20131694."},{"key":"B37","series-title":"J Clin Oncol","first-page":"1698","article-title":"Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma","volume":"26","author":"Jassem J","year":"2008","unstructured":"Jassem J, Ramlau R, Santoro A,  Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008;26:1698\u20131704."},{"key":"B38","series-title":"BMC Res Notes","first-page":"482","article-title":"Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience","volume":"5","author":"Bearz A","year":"2012","unstructured":"Bearz A, Talamini R, Rossoni G,  Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience. BMC Res Notes 2012;5:482."},{"key":"B39","series-title":"Lung Cancer","first-page":"73","article-title":"Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma","volume":"72","author":"Ceresoli GL","year":"2011","unstructured":"Ceresoli GL, Zucali PA, De Vincenzo F,  Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer 2011;72:73\u201377."},{"key":"B40","series-title":"J Clin Oncol","first-page":"1343","article-title":"Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Kindler HL","year":"2018","unstructured":"Kindler HL, Ismaila N, Armato SG III,  Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2018;36:1343\u20131373."},{"key":"B41","series-title":"Am J Surg Pathol","first-page":"653","article-title":"Pediatric mesothelioma with ALK fusions: a molecular and pathologic study of 5 cases","volume":"45","author":"Argani P","year":"2021","unstructured":"Argani P, Lian DWQ, Agaimy A,  Pediatric mesothelioma with ALK fusions: a molecular and pathologic study of 5 cases. Am J Surg Pathol 2021;45:653\u2013661."},{"key":"B42","series-title":"JCO Precis Oncol","article-title":"STRN-ALK fusion in a case of malignant peritoneal mesothelioma: mixed response to crizotinib, mode of resistance, and brigatinib sequential therapy","volume":"5","author":"Gerthofer V","year":"2021","unstructured":"Gerthofer V, Scheiter A, L\u00fcke F,  STRN-ALK fusion in a case of malignant peritoneal mesothelioma: mixed response to crizotinib, mode of resistance, and brigatinib sequential therapy. JCO Precis Oncol 2021;5:PO.21.00184."},{"key":"B43","series-title":"JCO Precis Oncol","article-title":"STRN-ALK rearranged malignant peritoneal mesothelioma with dramatic response following ceritinib treatment","volume":"3","author":"R\u00fcschoff JH","year":"2019","unstructured":"R\u00fcschoff JH, Gradhand E, Kahraman A,  STRN-ALK rearranged malignant peritoneal mesothelioma with dramatic response following ceritinib treatment. JCO Precis Oncol 2019;3:PO.19.00048."},{"key":"B44","series-title":"JTO Clin Res Rep","first-page":"100236","article-title":"Malignant peritoneal mesothelioma with EWSR1-ATF1 fusion: a case report","volume":"2","author":"Ke H","year":"2021","unstructured":"Ke H, Gill AJ, McKenzie C,  Malignant peritoneal mesothelioma with EWSR1-ATF1 fusion: a case report. JTO Clin Res Rep 2021;2:100236."},{"key":"B45","series-title":"Lancet Oncol","first-page":"1213","article-title":"Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in","volume":"21","author":"Nowak AK","year":"2020","unstructured":"Nowak AK, Lesterhuis WJ, Kok PS,  Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol 2020;21:1213\u20131223."},{"key":"B46","series-title":"Nat Med","first-page":"1910","article-title":"Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial","volume":"27","author":"Forde PM","year":"2021","unstructured":"Forde PM, Anagnostou V, Sun Z,  Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nat Med 2021;27:1910\u20131920."},{"key":"B47","series-title":"J Clin Oncol","first-page":"LBA8505","article-title":"IND227 phase III (P3) study of cisplatin\/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): a CCTG, NCIN, and IFCT trial","volume":"41","author":"Chu QS","year":"2023","unstructured":"Chu QS, Piccirillo MC, Greillier L,  IND227 phase III (P3) study of cisplatin\/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): a CCTG, NCIN, and IFCT trial. J Clin Oncol 2023;41(Suppl):Abstract LBA8505."},{"key":"B48","series-title":"AME Surg J","first-page":"15","article-title":"Role of induction and adjuvant systemic treatment in mesothelioma: narrative review","volume":"2","author":"Edelman MJ","year":"2022","unstructured":"Edelman MJ. Role of induction and adjuvant systemic treatment in mesothelioma: narrative review. AME Surg J 2022;2:15."},{"key":"B49","series-title":"PLoS One","first-page":"e0275187","article-title":"A single-center retrospective cohort study of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma","volume":"17","author":"Wang X","year":"2022","unstructured":"Wang X, Katz S, Miura J,  A single-center retrospective cohort study of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma. PLoS One 2022;17:e0275187."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/8\/article-e247031.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/8\/article-e247031.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/8\/article-e247031.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T12:47:31Z","timestamp":1729082851000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/8\/article-e247031.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":49,"journal-issue":{"issue":"8"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2024.7031","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]}}}